Iambic Therapeutics Prices IPO at $16 Per Share on Nasdaq

3-line summary

• Clinical-stage life sciences company Iambic Therapeutics (Nasdaq: IAM) priced its IPO at $16.00 per share, offering 9,375,000 shares of common stock for expected gross proceeds of $150.0 million before fees, per Investing.com. Underwriters have a 30-day option to purchase up to an additional 1,406,250 shares.
• Trading is expected to begin October 15, 2026 on the Nasdaq Global Select Market, with the offering set to close October 16. J.P. Morgan, Jefferies, BofA Securities and Citigroup are underwriting the deal; the registration statement became effective October 14.

This summary is our own processing of the source article; see the source link below for full context.